SEC Form 4 · accession 0000904454-15-000266
Tobira Therapeutics, Inc. · TBRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Jesse I Treu
10% Owner
DOMAIN ASSOCIATES
10% Owner
James C Blair
10% Owner
Nicole Vitullo
10% Owner
Brian H Dovey
10% Owner
Kathleen K Schoemaker
10% Owner
Brian K Halak
10% Owner
Kim P. Kamdar
10% Owner
Period of report
May 4, 2015
Accepted (ET)
May 6, 2015 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001311596
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF6,F7,F1,F2,F3,F4,F5 | May 4, 2015 | J | 36,187 | — | A | 38,094 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- F2As managing members of the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below (except for Kim P. Kamdar) may also be deemed to indirectly beneficially own 47,613 shares of Common Stock held by DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- F3As managing members of the sole general partner of Domain Partners VI, L.P., each Reporting Owner listed below (except for Brian K. Halak and Kim P. Kamdar) may also be deemed to indirectly beneficially own 285,679 shares of Common Stock held by Domain Partners VI, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VI, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- F4As managing members of the sole general partner of DP VI Associates, L.P., each Reporting Owner listed below (except for Brian K. Halak and Kim P. Kamdar) may also be deemed to indirectly beneficially own 1,657 shares of Common Stock held by DP VI Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VI Associates, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- F5As managing members of the sole general partner of Domain Partners VII, L.P., each Reporting Owner listed below (except for Kim P. Kamdar) may also be deemed to indirectly beneficially own3,553,322 shares of Common Stock held by Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- F6Received in exchange for 25,302 shares of Tobira Therapeutics, Inc. ("Tobira") common stock in connection with the merger of Landmark Merger Sub Inc., a wholly owned subsidiary of the Issuer (then named Regado Biosciences, Inc.) with and into Tobira, with Tobira surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Each share of Tobira common stock outstanding immediately prior to the Merger was converted into the right to receive approximately 11.4521 shares of Common Stock. After the completion of the Merger, the Issuer changed its name to "Tobira Therapeutics, Inc."
- F7The number of shares of Common Stock held by the designated Reporting Person prior to the Merger is adjusted to reflect the one-for-nine reverse split of the Common Stock that was effective prior to the Merger.